Amphastar pharmaceuticals reports financial results for the three months ended september 30, 2025

Reports net revenues of $191.8 million for the three months ended september 30, 2025 gaap net income of $17.4 million, or $0.37 per share, for the third quarter adjusted non-gaap net income of $44.7 million, or $0.93 per share, for the third quarter company to hold a conference call today at 2:00 p.m. pacific time rancho cucamonga, ca / access newswire / november 6, 2025 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended september 30, 2025.
AMPH Ratings Summary
AMPH Quant Ranking